Abstract
Abstract Unleashing the immune response against pulmonary premalignancy could transform therapy and outcomes. We are evaluating the mutational landscape of pulmonary premalignancy and the associated premalignant microenvironment by whole-exome DNA sequencing and immunohistochemistry. Remarkably, we find putative neoepitopes and frequent immune-effector cell infiltration as well as evidence of immune suppression in pulmonary premalignancy. These findings suggest that premalignant-associated antigens are recognized and elicit immune responses at the earliest points of lung adenocarcinoma development. Identification of neoepitopes that can be targeted before the development of invasive lung cancer could eventually shift the approach to disease interception through immunoprevention and treatment of the very earliest phase of the disease. Citation Format: Kostyantyn Krysan, Linh M. Tran, Brandon S. Grimes, Steven M. Dubinett. Inflammation and immunity in pulmonary premalignancy [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA09.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
